Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surfaxin for BPD Prevention in VLBW Infants
NCT00215540Phase 2Terminated
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Feb 2005
- Primary completion
- Jul 2006
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lucinactant in bronchopulmonary dysplasia (BPD), sponsored by Windtree Therapeutics, Inc.. Started Feb 2005; status: terminated.
02
Drugs
lucinactant
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT00215540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215540.